Clinical trials of antibody therapy

Immunology Today

Volumn 21, Issue 8, 2000, Pages 403-410

  Glennie, Martin J ^a   Johnson, Peter W M ^a  

^a UNIVERSITY OF SOUTHAMPTON   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ABCIXIMAB; ALEMTUZUMAB; BETA1 INTEGRIN; CD18 ANTIGEN; CD3 ANTIGEN; CD4 ANTIGEN; CD64 ANTIGEN; CHIMERIC ANTIBODY; COMPLEMENT COMPONENT C5; EDRECOLOMAB; FC RECEPTOR; GLYCOPROTEIN GP 39; IMMUNOGLOBULIN E; IMMUNOGLOBULIN G; INFLIXIMAB; INTERLEUKIN 2 RECEPTOR; INTERLEUKIN 2 RECEPTOR ANTIBODY; INTERLEUKIN 5; IODINE 131; MONOCLONAL ANTIBODY; MONOCLONAL ANTIBODY CD3; MONOCLONAL ANTIBODY LM 609; OKT 3; OKT 4; PALIVIZUMAB; RITUXIMAB; SEVIRUMAB; TOSITUMOMAB; TRASTUZUMAB; TUMOR NECROSIS FACTOR ALPHA ANTIBODY; UNINDEXED DRUG;

ANTIGEN ANTIBODY REACTION; B CELL LYMPHOMA; BREAST CANCER; CANCER CHEMOTHERAPY; CLINICAL TRIAL; COLORECTAL CANCER; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CROHN DISEASE; CYTOTOXIC T LYMPHOCYTE; DRUG MECHANISM; DRUG TARGETING; GENETIC ENGINEERING; HUMAN; IMMUNE RESPONSE; IMMUNOGENICITY; LYMPHATIC LEUKEMIA; LYMPHOMA; MOUSE; NONHUMAN; PRIORITY JOURNAL; REVIEW; RHEUMATOID ARTHRITIS;

ANIMALS; ANTIBODIES, BLOCKING; ANTIBODIES, MONOCLONAL; ANTINEOPLASTIC AGENTS; ANTIRHEUMATIC AGENTS; CLINICAL TRIALS; DRUG DESIGN; HUMANS; IMMUNOGLOBULIN FC FRAGMENTS; IMMUNOSUPPRESSIVE AGENTS; MICE; NEOPLASMS; RECOMBINANT FUSION PROTEINS; SIGNAL TRANSDUCTION;

EID: 0033855859     PISSN: 01675699     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0167-5699(00)01669-8     Document Type: Review

References (50)

1. Treatment of B-cell lymphoma with monoclonal anti-idiotype antibody
2. Cancer therapy - Antibodies stage a comeback in cancer treatment
3. Immunotherapy of endotoxemia and septicemia
4. Signaling antibodies in cancer therapy
5. The development of monoclonal antibodies for the therapy of cancer
6. A review of interleukin-2 receptor antagonists in solid organ transplantation
7. Infliximab (chimeric anti-tumour necrosis factor alpha monoclonal antibody) versus placebo in rheumatoid arthritis patients receiving concomitant methotrexate: A randomised phase III trial
8. Antitumor necrosis factor therapy for inflammatory bowel disease: A review of agents, pharmacology, clinical results and safety
9. Safety and pharmacokinetics of an intramuscular humanized monoclonal antibody to respiratory syncytial virus in premature infants and infants with bronchopulmonary dysplasia
10. Acute profound thrombocytopenia following C7E3 Fab (abciximab) therapy: Case reports, review of the literature and implications for therapy
11. The rise of monoclonal antibodies as therapeutics
12. Human antibodies by design
13. Final report on the safety and efficacy of retreatment with rituximab for patients with non-Hodgkin's lymphoma
14. Monoclonal antibody therapy for resected Dukes' C colorectal cancer: Seven-year outcome of a multicenter randomized trial
15. Iodine-131 Tositumomab for patients with follicular non-Hodgkin's lymphoma (NHL): Overall clinical trial experience by histology
16. FcRn: The MHC class I-related receptor that is more than an IgG transporter
17. A short-term study of chimeric monoclonal antibody cA2 to tumor necrosis factor alpha for Crohn's disease
18. Endoscopic and histological healing with infliximab anti-tumor necrosis factor antibodies in Crohn's disease: A European multicenter trial
19. Infliximab for the treatment of fistulas in patients with Crohn's disease
20. Repeated therapy with monoclonal antibody to tumour necrosis factor alpha (cA2) in patients with rheumatoid arthritis
21. Treatment of acute graft-versus-host disease with methylprednisolone and cyclosporine with or without an anti-interleukin-2 receptor monoclonal antibody - A multicenter phase III study
22. Rituximab chimeric anti-CD20 monoclonal antibody therapy for relapsed indolent lymphoma: Half of patients respond to a four-dose treatment program
23. European Phase II study of rituximab (chimeric anti-CD20 monoclonal antibody) for patients with newly diagnosed mantle-cell lymphoma and previously treated mantle-cell lymphoma, immunocytoma, and small B-cell lymphocytic lymphoma
24. Apoptosis of malignant human B cells by ligation of CD20 with monoclonal antibodies
25. How do monoclonal antibodies induce tolerance? A role for infectious tolerance
26. Regulation of the complement membrane attack pathway
27. Transduction of cytotoxic signals in natural killer cells: A general model of fine tuning between activatory and inhibitory pathways in lymphocytes
28. Fc receptors are required in passive and active immunity to melanoma
29. Inhibitory Fc receptors modulate in vivo cytotoxicity against tumor targets
30. Campath-1H therapy in 29 patients with refractory CLL: 'True' complete remission is an attainable goal
31. Effects of Campath-1 antibodies in vivo in patients with lymphoid malignancies - Influence of antibody isotype
32. Lymphoma regression induced by monoclonal anti-idiotypic antibodies correlates with their ability to induce Ig signal transduction and is not prevented by tumour expression of high levels of Bcl-2 protein
33. Monoclonal antibody therapy of B cell lymphoma: Signaling activity on tumor cells appears more important than recruitment of effectors
34. Tumor dormancy and signaling (V): Regrowth of the BCL1 tumor after dormancy is established
35. Trastuzumab, a recombinant DNA-derived humanized monoclonal antibody, a novel agent for the treatment of metastatic breast cancer
36. The association between CD20 and Src-family tyrosine kinases requires an additional factor
37. Mice carrying a CD20 gene disruption
38. Rapid redistribution of CD20 to a low density detergent-insoluble membrane compartment
39. The CD40 antigen and its ligand
40. Soluble CD40 ligand induces proliferation rather than apoptosis in primary human low-grade lymphoma: Implications for immunotherapy
41. Radioimmunotherapy of B-cell lymphoma: The importance of antibody-specificity in determining successful treatment of established disease
42. I-131 anti-P1 antibody for previously untreated follicular lymphoma (FL): Clinical and molecular remissions
43. Phase II trial of I-131-B1 (anti-CD20) antibody therapy with autologous stem cell transplantation for relapsed B cell lymphomas
44. Iodine-131-anti-B-1 radioimmunotherapy for B-cell lymphoma
45. Prospective randomized controlled study of Zevalin (TM) (IDEC-Y2B8) radioimmunotherapy compared to rituximab immunotherapy for B-cell NHL: Report of interim results
46. Enhancement of antitumor immunity by CTLA-4 blockade
47. CD40 antibody evokes a cytotoxic T-cell response that eradicates lymphoma and bypasses T-cell help
48. Monoclonal antibodies against 4-1BB T-cell activation molecule eradicate established tumors
49. A lymphocyte-activating monoclonal antibody induces regression of human tumors in severe combined immunodeficient mice
50. The Renaissance of Antibodies